Medrol-dose pack (Steroid)

Phase 2Small molecule

UUniversity of Louisville

Medrol-dose pack (Steroid) is one of 8 small molecule programs targeting Skin rash. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin RashActive, not recruiting

Skin RashPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Skin Rash

#DrugCompanyPhaseTrials

Soriatane

GSK

Approved

1 2

Elidel

BBausch Health Americas, Inc.

Acanya

1 4

Lamictal

GGlaxo Dba Glaxosmithkline

Phase 2

1 5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

Sunscreen

YYale University

Phase 3

1 7

Medrol-dose pack (Steroid)

UUniversity of Louisville

Phase 2

1 8

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Skin rash1 trial

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Completed·UUniversity of Louisville·Phase 2·NCT01874860·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Medrol-dose pack (Steroid). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Medrol-dose pack (Steroid) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Medrol-dose pack (Steroid). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Louisville company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Louisville

Medrol-dose pack (Steroid)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Skin rash1 trial

References

Drug Info

Quick Facts

Related News